Condition
Idiopathic Pulmonary Fibrosis, Acute Fatal Form
Total Trials
1
Recruiting
0
Active
0
Completed
1
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Treatment Research
2 treatments under study, led by Autoantibody Reductive Therapy
Research Leaders
5 sponsors active, led by Temple University
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 25/100
Termination Rate
0.0%
0 terminated out of 1 trials
Success Rate
100.0%
+13.4% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
100%
1 of 1 completed with results
Key Signals
1 with results100% success
Data Visualizations
Phase Distribution
1Total
Phase 2 (1)
Trial Status
Completed1
Trial Success Rate
100.0%
Benchmark: 86.6%
Based on 1 completed trials
Clinical Trials (1)
Showing 1 of 1 trials
Showing all 1 trials
Research Network
Common Treatments
- Autoantibody Reductive Therapy1
- Treatment As Usual Tau1
Active Sponsors
- Temple University1
- Brigham and Women's Hospital1
- National Heart, Lung, and Blood Institute (NHLBI)1
- University of Alabama at Birmingham1
- University of Pittsburgh1